POMPE DISEASE TREATMENT - ACID ALPHA-GLUCOSIDASE DEFICIENCY
DOI:
https://doi.org/10.14450/2318-9312.v26.e3.a2014.pp179-187Keywords:
glycogen storage disease type II, metabolism, inborn errors, glycogenAbstract
The aim of this paper is to describe the pathogenesis and treatment of Pompe disease. A bibliographic review was performed by searching scientific papers published between 2004 and 2014. Patients with deficiency in the enzyme acid alpha-glucosidase, develop Pompe disease, which results in an accumulation of glycogen within (inside) lysosome, causing damage and organ dysfunction in muscle tissue, with difficulty in breathing, locomotion, speech and hearing. The enzyme replacement therapy is the specific alternative to treatment for Pompe, significantly improving cardiac function and mortality reduction. However, the need for injection of large doses of enzyme, and loss of 80% of the enzyme due to high hepatic metabolism and the treatment cost hamper their use. The dose which showed the best results was 20 mg/kg of the enzyme once every two weeks. However, despite the high cost of treatment, the benefits of decreased symptoms in patients are important, such as the improvement in performing activities of daily living, increased muscle strength, reduced fatigue and improves pulmonary function. There are also alternative treatments, but are still under study. Among the treatments, the one with a better prognosis is replacement with recombinant human enzyme. The enzyme replacement therapy many patients brought survival due to decreased cardiac hypertrophy and improvement in motor symptoms.Downloads
Published
2014-09-17
How to Cite
Kuhn, M. I., Borges, V., & Bock, P. M. (2014). POMPE DISEASE TREATMENT - ACID ALPHA-GLUCOSIDASE DEFICIENCY. Infarma - Pharmaceutical Sciences, 26(3), 179–187. https://doi.org/10.14450/2318-9312.v26.e3.a2014.pp179-187
Issue
Section
Review Article
License
Authors who publish in this journal agree to the following terms:
- Authors retain the copyright and grant the journal the right of first publication, with the work simultaneously licensed under the Licença Creative Commons Attribution which allows the sharing of work with acknowledgment of authorship and initial publication in this journal.
- Authors are authorized to take additional contracts separately, for non-exclusive distribution of the version of the work published in this journal (e.g. publish in institutional repository or as a book chapter), with acknowledgment of authorship and initial publication in this journal.
- Authors are allowed and encouraged to publish and distribute their work online (e.g. in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes as well as increase the impact and Citation of published work (See O Efeito do Acesso Livre ).